Literature DB >> 19934758

Netrin-1 and its dependence receptors as original targets for cancer therapy.

Patrick Mehlen1, Céline Guenebeaud.   

Abstract

PURPOSE OF REVIEW: The dependence receptor notion has recently seen an interesting development. From a basic cell biology concept, which proposes that some transmembrane receptors can be active in the absence of their ligand and induce in the setting apoptosis, recent observations have provided new hope for the development of alternative targeted therapies. The purpose of this review is to show, with the example of netrin-1 dependence receptors, the path from cell biology to promising anticancer-targeted therapy. RECENT
FINDINGS: The dependence receptors Deleted in Colorectal Cancer and Unc-5 homolog that bind netrin-1 had been implicated in nervous system development as they participate in neuronal navigation. They were also implicated beyond the developing brain with roles in angiogenesis regulation and homeostasis of various tissues. However, these receptors were shown to trigger apoptosis in the absence of netrin-1 and, as such, act as tumor suppressors. Recent data support the view that Deleted in Colorectal Cancer/Unc-5 homolog proapoptotic signals are indeed a safeguard mechanism regulating tumor growth and metastasis.
SUMMARY: In this review, we will develop the different data supporting the view that a selective advantage for a tumor is to inactivate this dependence receptor's proapoptotic signal and will describe a putative therapeutic approach that is to reactivate this death signaling in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19934758     DOI: 10.1097/CCO.0b013e328333dcd1

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  41 in total

1.  Dependence receptors: mechanisms of an announced death.

Authors:  Chantal Thibert; Joanna Fombonne
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

Review 2.  The role of UNC5C in Alzheimer's disease.

Authors:  Quan Li; Bai-Ling Wang; Fu-Rong Sun; Jie-Qiong Li; Xi-Peng Cao; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

3.  Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability.

Authors:  Qi Qi; Dean Y Li; Hongbo R Luo; Kun-Liang Guan; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-26       Impact factor: 11.205

4.  Intranasal administration of recombinant Netrin-1 attenuates neuronal apoptosis by activating DCC/APPL-1/AKT signaling pathway after subarachnoid hemorrhage in rats.

Authors:  Zongyi Xie; Lei Huang; Budbazar Enkhjargal; Cesar Reis; Weifeng Wan; Jiping Tang; Yuan Cheng; John H Zhang
Journal:  Neuropharmacology       Date:  2017-03-24       Impact factor: 5.250

Review 5.  Role of netrin-1 in the organization and function of the mesocorticolimbic dopamine system.

Authors:  Cecilia Flores
Journal:  J Psychiatry Neurosci       Date:  2011-09       Impact factor: 6.186

6.  Netrin-1 induces epithelial-mesenchymal transition and promotes hepatocellular carcinoma invasiveness.

Authors:  Wei Yan; Ping Han; Zhenzhen Zhou; Wei Tu; Jiazhi Liao; Peiyuan Li; Mei Liu; Dean Tian; Yu Fu
Journal:  Dig Dis Sci       Date:  2014-01-18       Impact factor: 3.199

7.  Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus.

Authors:  M-L Plissonnier; T Lahlali; M Raab; M Michelet; C Romero-López; M Rivoire; K Strebhardt; D Durantel; M Levrero; P Mehlen; F Zoulim; R Parent
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

8.  Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases.

Authors:  Ganesan Ramesh
Journal:  Recent Pat Biomark       Date:  2012-09

9.  PKCα is involved in the progression of kidney carcinoma through regulating netrin-1/UNC5B signaling pathway.

Authors:  Bo Zhan; Chuize Kong; Kunfeng Guo; Zhe Zhang
Journal:  Tumour Biol       Date:  2013-03-23

Review 10.  Antiangiogenic therapy for cancer: an update.

Authors:  Belal Al-Husein; Maha Abdalla; Morgan Trepte; David L Deremer; Payaningal R Somanath
Journal:  Pharmacotherapy       Date:  2012-12       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.